What if your prostate cancer plan was just “shut down testosterone and hope for the best”?
That’s the reality for many patients — fatigue, weight gain, brain fog, and a life defined by side effects. In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares Bob’s story, a late-stage prostate cancer patient whose PSA was rising and bones were lighting up with metastases. Instead of following the same failing playbook, Bob chose precision oncology — and it changed everything.
Using deep mapping (DNA, RNA, immune profiling, and spatial biology), Dr. Prato’s team uncovered resistance markers and immune barriers that standard care missed. The result: a custom plan combining genetically targeted fractionated chemotherapy (GTF), direct-to-tumor chemo-immuno precision injection (CIPI), and immune reactivation through DAMP signaling. By restoring immune function and delivering therapy straight to the tumor, Bob’s PSA normalized, bone pain resolved, and his energy — and life — returned.
🎯 What You’ll Learn in This Episode:

• Why testosterone suppression alone fails many advanced prostate cancer patients

• The real difference between hormone blockade and immune-centered precision care

• How DNA, RNA, and spatial mapping reveal hidden cancer drivers

• The role of DAMPs in activating immune response and destroying cold tumors

• How GTF and CIPI deliver 100% precision targeting with 10% chemo dose

• Why precision oncology improves both outcomes and quality of life
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493